At 03:58 P.M. (GMT+7), the share price of Praram 9 Hospital Public Company Limited (SET: PR9) stood at THB 18.90 per share, up THB 0.90 or 5.00%, with a trading value of THB 38.08 million, after the company assured that the co-payment health insurance system will not affect the business.
Ms. Kamaporn Tumpipit, Deputy Chief Executive Officer of Accounting, Finance, and Administration at PR9, told “Kaohoon” that regarding the rumor that a major insurance company will stop selling full coverage health insurance, the situation remains unclear and no concrete actions have been taken by the major insurers.
Additionally, it is necessary to monitor whether the Office of Insurance Commission (OIC) will issue regulations or negotiate further with policyholders in the long term.
Meanwhile, if insurers switch to offering only co-payment health insurance plans for new policyholders, the company expects there will be no impact and can manage efficiently. This is because PR9’s insured patients account for approximately 24–25% of all patients, with most already paying for excess charges during treatment.
Most health insurance plans currently provide limited coverage for room fees, as insurers consider this an extravagance. Instead, they focus coverage on medication, lab, treatment, and doctor fees. For room charges, PR9 already has patient assistance programs in place.
For its 2026 operational plan, PR9 targets double-digit growth in medical service revenue compared to 2025, in line with the increasing number of Thai and foreign patients, thanks to the hospital’s focus on attracting patients with complex or specialized conditions.
Furthermore, PR9 plans to invest around THB 200–300 million, emphasizing investments in innovative or advanced medical technology and equipment to ensure patients receive optimal and efficient treatment outcomes.
For the overall performance in 4Q25, growth is expected compared to the previous quarter and the same period last year. This is due to companies sending a large number of employees for annual health checkups, as well as a positive impact from seasonal diseases, whose outbreak shifted from 3Q to early 4Q, leading to increased outpatient (OPD) visits combined with an expansion of specialized treatment.
As a result, inpatient (IPD) bed occupancy rates remained high at over 70%, despite tighter insurance regulations. The Board of Directors will convene to approve the 2025 financial results, which will be announced on February 18, 2026.
For the full year 2025, the company is confident that medical service revenue will achieve double-digit growth compared to 2024, when revenue was about THB 4.7 billion. In the first nine months of 2025, medical service revenue reached THB 3.97 billion.
This aligns with the company’s strategy of maintaining a strong Thai patient base even amid a sluggish economy, and the growing number of foreign patients, accounting for approximately 25–26% of total patients, with the majority being from the Middle East, the CLMV countries (Cambodia, Laos, Myanmar, Vietnam), and China.
